https://stockhub.co/index.php?action=history&feed=atom&title=GlycoNex_Incorporation 2026-05-25T09:09:31Z Revision history for this page on the wiki MediaWiki 1.43.5 https://stockhub.co/index.php?title=GlycoNex_Incorporation&diff=66036&oldid=prev 2022-09-20T19:24:49Z

<p>Created page with &quot;== Summary&lt;ref&gt;Source: Yahoo Finance.&lt;/ref&gt; == GlycoNex Incorporation develops cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. Its technology platform enables glycan-directed cancer therapy and analytical tools for glycosylation. The company develops GNX102, a humanized antibody for cancer; and GNX201, GNX202, GNX203, and GNX204 for various solid tumors. It also develops Denosumab, a humanized IgG2 antibody that is in p...&quot;</p> <p><b>New page</b></p><div>== Summary&lt;ref&gt;Source: Yahoo Finance.&lt;/ref&gt; ==<br /> <br /> GlycoNex Incorporation develops cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. Its technology platform enables glycan-directed cancer therapy and analytical tools for glycosylation. The company develops GNX102, a humanized antibody for cancer; and GNX201, GNX202, GNX203, and GNX204 for various solid tumors. It also develops Denosumab, a humanized IgG2 antibody that is in preclinical stage for the treatment of osteoporosis and oncology; and Aflibercept, a vascular endothelial growth factor binding fusion protein for the treatment of ophthalmology and oncology. GlycoNex Incorporation was founded in 2001 and is based in New Taipei City, Taiwan.<br /> <br /> == References and notes == <br /> [[Category:Thesis]]<br /> __INDEX__</div>

>Nick